On December 19, 2024, Michael Garrison, Executive Vice President & President, Medical at Becton Dickinson & Co (BDX, Financial), sold 2,838 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 6,141 shares of the company.
Becton Dickinson & Co (BDX) is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. It serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.
Over the past year, Michael Garrison has sold a total of 4,553 shares and has not purchased any shares. The insider transaction history for Becton Dickinson & Co shows that there have been no insider buys in total over the past year, while there have been nine insider sells during the same period.
On the day of the recent sale, shares of Becton Dickinson & Co were trading at $223.33, giving the stock a market cap of $66.33 billion. The company's price-earnings ratio is 38.51, which is higher than the industry median of 28.01 but lower than the company’s historical median price-earnings ratio.
With a price of $223.33 and a GF Value of $260.81, Becton Dickinson & Co has a price-to-GF-Value ratio of 0.86, indicating that the stock is modestly undervalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
